ABUS Arbutus Biopharma Corp
17,195
$2.88
$0.06
(2.04%)
| Watchers | 17,195 |
| 52-Wk Low | $1.69 |
| 52-Wk High | $3.29 |
| Market Cap | $554.83M |
| Volume | 697,958.00 |
| 52-Wk High | $3.29 |
| 52-Wk Low | $1.69 |
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against ModernaGlobe Newswire • about 1 month ago
WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
Share to Feed
Arbutus Biopharma Co. (NASDAQ:ABUS Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.24 and traded as...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Investors considering a purchase of Arbutus Biopharma Corp (ABUS) stock, but cautious about paying the going market price of 2.56/share, might benefit from considering selling puts among the...
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
Arbutus Biopharma Co. (NASDAQ:ABUS Get Free Report) saw a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 3,690,000...
Arbutus Biopharma GAAP EPS of -$0.44 beats by $0.01, revenue of $18.1M misses by $3.04M...
On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical...
Barclays PLC lifted its stake in Arbutus Biopharma Co. (NASDAQ:ABUS Free Report) by 175.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange...